Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for WUCT aggregates regulatory documents tied to ETRACS Whitney US Critical Technologies ETNs issued by UBS AG, a foreign private issuer. The core filings here are Forms 6-K, which provide interim financial and legal updates that are incorporated by reference into UBS AG’s Form F-3 registration statement for securities offerings.
In these Form 6-K reports, UBS AG discloses consolidated capitalization in US dollars under IFRS Accounting Standards, detailing short-term and long-term debt issued by UBS AG and its subsidiaries, funding from UBS Group AG, equity attributable to shareholders and non-controlling interests, and total capitalization. Such information helps investors understand the broader balance sheet context of the issuer behind the WUCT-linked ETNs.
The filings also explain how specific 6-K reports are incorporated into UBS AG’s Form F-3 registration statement and any outstanding prospectuses or offering circulars that reference those 6-Ks. This structure means that updates filed on Form 6-K become part of the official documentation for securities, including the ETRACS Whitney US Critical Technologies ETNs associated with WUCT.
Another Form 6-K on this page consists of the opinion of Homburger AG, acting as special Swiss counsel to UBS AG, which is filed as an exhibit to the Form F-3 registration statement and replaces a prior opinion. This highlights the role of legal opinions in UBS AG’s securities registration process.
On Stock Titan, users can access these filings in one place, with AI-powered tools available to summarize key sections, highlight important capitalization and legal disclosures, and help interpret how each new Form 6-K or related document fits into UBS AG’s overall reporting framework for the WUCT-linked ETNs.
UBS AG London Branch is offering Contingent Income Auto-Callable Securities with Memory Coupon due on or about 19 January 2029, linked to the common stock of Merck & Co., Inc. (MRK). Each $1,000 security pays a contingent coupon of $28.25 (11.30% p.a.) on the scheduled quarterly payment dates only when Merck’s closing price on the corresponding determination date is at least 75 % of the initial price (the “downside threshold”). Missed coupons are not lost; they accrue and are paid later if a subsequent determination date meets the threshold (the “memory” feature).
The securities can be automatically called after any determination date—starting 16 October 2025—if Merck closes at or above 100 % of the initial price (the “call threshold”). In that event investors receive (i) the $1,000 principal and (ii) the current coupon plus all previously unpaid coupons, but forfeit future upside participation and further coupons.
Principal repayment is not guaranteed. If the notes are not called and Merck is below 75 % of the initial price on the final determination date (16 January 2029), UBS will pay a cash amount equal to the exchange ratio ( $1,000 ÷ initial price) multiplied by the final price—resulting in a loss of 1-for-1 with Merck’s decline beyond the 25 % buffer and potentially the total loss of principal. If Merck finishes at or above the downside threshold, investors receive full principal plus the final coupon and any accrued coupons.
Key economic terms:
- Coupon rate: 11.30% p.a. (paid quarterly if conditions met)
- Downside threshold: 75 % of initial price
- Call threshold: 100 % of initial price
- Estimated initial value: 93.37 % – 96.37 % of issue price (reflects 2.50 % total selling concessions and UBS funding spread)
- Maturity: ~42 months, unlisted, secondary market making at UBS’s discretion
- Credit risk: Unsecured, unsubordinated obligations of UBS AG; all payments subject to UBS creditworthiness
The filing details extensive risk factors, including market risk in MRK, coupon uncertainty, early-call reinvestment risk, illiquidity, complex tax treatment (Section 871(m), FATCA), and potential Swiss resolution powers over UBS. Investor suitability highlights the need to tolerate significant price volatility, possible coupon gaps, and potential full loss of capital.